OBJECTIVE: @entity1 with @entity151 ( @entity151 ) are at high risk of developing brain @entity3 (BM). Fractionated stereotactic radiotherapy (FSRT) alone or combined with whole brain radiation therapy can be used to treat intracranial @entity3 . This study was aimed to explore FSRT for BM from @entity151 . MATERIALS AND METHODS: We retrospectively analyzed 45 @entity1 with BM from @entity151 treated with fractionated linear accelerator FSRT. Multivariate analysis was used to determine independent risk factors of @entity1349 ( @entity1349 ). RESULTS: There were 35 @entity1 treated with salvage FSRT and 10 @entity1 treated with primary FSRT. The median @entity1349 was 10 months from the beginning of FSRT and 19 months from diagnosis of BM. The median @entity1349 of salvage FSRT group and primary FSRT group was 22 and 10 months from the diagnosis of BM, respectively (P = 0.011); 11 and 8 months from FSRT, respectively (P = 0.828). Recursive partitioning analysis class and the stage of the primary @entity5 were independent predictors of increased @entity1349 (relative risk [RR] = 2.634, P = 0.021 and RR = 2.324, P = 0.0210, respectively). CONCLUSIONS: Salvage and primary FSRT were both effective treatment options for BM from @entity151 . Salvage and primary FSRT may have different @entity1349 from the time of diagnosis of BM.

Fractionated stereotactic radiotherapy for @entity151 XXXX with brain @entity3 .

@entity1 :: ('9606', 'Species') :: ['Patients', 'patients'] @entity5 :: ('MESH:D009369', 'Disease') :: ['tumor'] @entity3 :: ('MESH:D009362', 'Disease') :: ['metastases'] @entity151 :: ('MESH:D055752', 'Disease') :: ['SCLC', 'small-cell lung cancer'] @entity1349 :: ('MESH:D011475', 'Disease') :: ['OS', 'overall survival']
@entity1 :: (9606,Species) :: ['patients']
